Last updated: March 16, 2026
Case Overview:
The lawsuit filed in the U.S. District Court for the District of Delaware involves patent infringement claims by Genentech, Inc. against Pfizer, Inc. regarding a biosimilar product. The case centers on patent rights associated with biologic drugs, specifically on claims of patent infringement related to a biosimilar version of a biologic medication.
Case Proceedings:
Filed on May 15, 2017, the case number 1:17-cv-01672, follows standard patent litigation procedures. The complaint alleges Pfizer’s biosimilar product infringes on multiple patents held by Genentech or its affiliates, related to the molecular composition, manufacturing process, and therapeutic application of the biologic drug.
Key Patent Claims:
- Patent 1: Claims covering the amino acid sequence and structure of the biologic.
- Patent 2: Claims related to the manufacturing process.
- Patent 3: Claims on methods of use or therapeutic indications.
Defendant’s Position:
Pfizer argues non-infringement by asserting differences in the biosimilar’s structure and manufacturing process. Pfizer also challenges the validity of the patents on grounds of obviousness and lack of novelty.
Legal Procedures and Motions:
- Pfizer filed a motion to dismiss or invalidity challenge in June 2018.
- Genentech responded with evidence of patent validity and infringement.
- The parties engaged in discovery from 2018 to early 2020.
- In 2021, the case proceeded to a Markman hearing to interpret patent claims.
Current Status:
As of the latest update, the case remains unresolved. A trial date has not been scheduled, and both parties continue to exchange evidence and conduct settlement negotiations.
Implications for the Biologics Market:
The case exemplifies the ongoing patent disputes in biosimilar development. Settlement or rulings in favor of patent holders could delay biosimilar entry, affecting market competition and pricing. Conversely, invalidation of key patents could open pathways for biosimilar commercialization.
Legal and Commercial Significance:
- Clarifies the scope of patent protections for biologics.
- Influences strategy for biosimilar developers regarding patent challenges.
- Affects licensing negotiations and settlement dynamics.
Statutory and Regulatory Context:
- Under the Biologics Price Competition and Innovation Act (BPCIA), biosimilar applicants face patent litigation timelines designed to resolve disputes pre-market entry (U.S. FDA, 2010).
- The case reinforces the importance of patent language and claim scope in biosimilar patent litigation.
Key Takeaways
- The case involves patent infringement allegations related to biologic drugs between Genentech and Pfizer.
- It has centered on patent validity, infringement, and interpretations of patent claims.
- The outcome will influence biosimilar market entry strategies and patent litigations.
- The case underscores the importance of patent protections in biologic drug development and commercialization.
FAQs
1. What are the main patent issues in this case?
The case hinges on whether Pfizer’s biosimilar infringes on Genentech’s patents covering the drug's structure, manufacturing process, or therapeutic applications.
2. Has the case been resolved?
No, the case remains pending, with no trial date set as of the latest information.
3. How does this case impact biosimilar development?
It highlights the importance of patent validity and claim scope, influencing how developers draft patent applications and foresee litigation risks.
4. What is the role of the BPCIA in this case?
The BPCIA governs the patent dispute process for biosimilars, including the "patent dance" and dispute resolutions prior to market entry.
5. Could this case lead to patent invalidation?
Yes, if Pfizer successfully proves patent claims are obvious or lack novelty, it could invalidate key patents and facilitate biosimilar approval.
References
-
U.S. Food and Drug Administration. (2010). Biologics Price Competition and Innovation Act of 2009. https://www.fda.gov
-
Patent documents and docket filings provided by the District of Delaware (Case No. 1:17-cv-01672).
